CMIC becomes Align Clinical CRO member to enhance trial partnerships
Category: #health  By Mateen Dalal  Date: 2019-07-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

CMIC becomes Align Clinical CRO member to enhance trial partnerships

The teaming up of CMIC with other companies will improve the collaboration and execution of clinical studies

CMIC Group, a leading Japanese Contract Research Organization (CRO) that provides complete range of pharmaceutical drug services, recently announced that it has joined Align Clinical CRO, an industry standards group for life sciences aimed at creating open tech standards that make it easier for CROs and sponsors to work together during trials.

Apparently, CMIC brings over 25 years of experience as a solution provider and operational expertise in clinical trial in Asia and is the first CRO from Japan to join the group. CMIC is teaming up with major CROs partners for the improvement of collaboration and execution during clinical studies.

CMIC is known as a strategic partner that helps sponsors in the rapid development of better medicines with solutions ranging from the development of drug to manufacturing, along with filing to post marketing surveillance.

CMIC HOLDINGS Co., Ltd.’s COO and President Keiko Oishi said that global healthcare sector  is witnessing a significant change. There is an increase in the number of global trials, the study designs are more complex, and the qualification requirements and the kind of service requests are changing as well. Being the member of Align Clinical CRO, the company is committed towards helping the industry increase productivity, run clinical trials efficiently and reduce the operational costs.

For the uninitiated, CMIC started business as the first CRO in Japan in 1992 and today, it provides comprehensive support services for the development of pharmaceutical products, manufacturing and sales and marketing of those products. The company also manages the healthcare business sector and develops as well as sells diagnostic orphan and pharmaceutical drugs, responding to the diversifying needs.

Based on CMIC Group’s accumulated knowledge and experience as a CRO pioneer, the company has developed a business model which is called Pharmaceutical Value Creator (PVC). The PVC is used by the company to create new value in the field of healthcare.

Source Credit- https://www.cmicgroup.com/e/news/20190710

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZenecas Farxiga gets fast track status to treat heart failure
AstraZenecas Farxiga gets fast track status to treat heart failure
By Mateen Dalal

With heart related issues and number of people diagnosed with heart failure increasing substantially, the need to find a solution to this problem is growing considerably. Advanced technology, equipment and pharmaceutical companies are continuously wo...

Upstream Works, Aceyus to pioneer customer experience solutions
Upstream Works, Aceyus to pioneer customer experience solutions
By Mateen Dalal

Customer Experience (CX) is vital for companies to understand the mindset of their clients. Industries are actively investing in customer experience solutions to stay ahead in competition. Companies are also partnering with other market players to en...

Patient data from Oncopeptides’ Phase 2 trial to be showcased at IMW
Patient data from Oncopeptides’ Phase 2 trial to be showcased at IMW
By Mateen Dalal

Patients having Relapsed-refractory multiple myeloma (RRMM) along with extramedullary disease (EMD) will be treated by Oncopeptides AB. In the company’s HORIZON trial, a cumulative response rate of 23% was attained with dexamethasone and mel...